

Specialty drugs

with cost-sharing

The drugs below are eligible for coverage under the medical benefit and may require member cost-sharing. Cost-sharing amounts are listed on the member's benefits summary. This list is subject to change. If you have any questions, call 1-800-275-2583 (TTY: 711).

Amyotrophic Lateral Sclerosis Agents

- NurOwn⁴

Anemia

- Aranesp
- Epogen
- Procrit

Bone-Modifying Agents

- Evenity

Botulinum Toxins

- Botox
- Dysport
- Myobloc
- Xeomin

Cystic Fibrosis

- Cayston
- Pulmozyme
- Tobi

Endocrine/Metabolic Agents

- Acthar HP
- Camcevi
- cosyntropin depot⁴
- Eligard
- Fensolvi
- Lupaneta
- Lupron depot
- Lutathera
- Sandostatin
- Sandostatin LAR
- Somatuline depot
- Supprelin LA
- Thyrogen
- Trelstar
- Triptodur
- Vantas
- Zoladex

Enzyme Replacement Agents

- Brineura
- Cerezyme
- Elelyso
- Elfabrio
- Fabrazyme
- Lumizyme
- Mepsevii
- Nexviazyme
- Pombiliti
- VPRIV
- Xenpozyme

Gene Replacement/ Gene Editing Therapies¹

- Beqvez
- Casgevy
- Hemgenix
- Lenmeldy
- Luxturna
- Lyfgenia
- marnetegrage autotemcel⁴
- prademagene zamikeracel⁴
- Roctavian
- Vyjuvek
- Zolgensma
- Zynteglo

Hemophilia/ Coagulation Factors¹

- Advate
- Adynovate
- Afstyla
- Alphanate
- Alphanine SD
- Alprolix
- Altuviiiio
- Bebulin VH
- BeneFIX
- Coagadex
- Corifact
- Eloctate
- Esperoct

What you need to know

- Specialty drugs tend to be more expensive, so these drugs may require higher member out-of-pocket costs.
- Members should check their medical benefits for specialty drug cost-sharing amounts.

- Feiba NF
- Feiba VH
- Fibryga
- Helixate FS
- Hemlibra
- Hemofil M
- Humate P
- Idelvion
- Ixinity
- Jivi
- Koate DVI
- Kogenate FS
- Kovaltry
- Monoclade P
- Mononine
- Novoeight
- Novoseven
- Novoseven RT
- Nuwiq
- Obizur
- Profilnine SD
- Rebinyn
- Recombinate
- RiaSTAP
- Rixubis
- Sevenfact
- Tretten
- Vonvendi
- Wilate
- Xyntha

Human Immunodeficiency Virus Agents

- Cabenuva
- Sunlenca
- Trogarzo

Hyaluronate Acid Products¹

- Durolane
- Euflexxa
- Gel-One
- Gelsyn-3
- GenVisc 850
- Hyalgan
- Hymovis
- Monovisc²
- Orthovisc²
- Supartz
- Synjoynt
- Synvisc²
- Synvisc-One²
- Trilon
- TriVISC
- VISC0-3

Immune Globulin¹

- Alyglo
- Asceniv
- Bivigam
- Cutaquig
- Cuvitru
- Flebogamma
- Flebogamma DIF
- Gamastan S/D
- Gammagard Liquid
- Gammagard S/D
- Gammaked
- Gammplex
- Gamunex-C
- Hizentra
- HyQvia
- Octagam
- Panzyga
- Privigen
- Xembify
- Yimmugo

Immunological Agents

- Actemra IV
- Avsola
- Benlysta IV
- Entyvio
- Ilumya
- Inflectra
- Infliximab (unbranded)
- Ixifi
- Omvoh IV
- Orencia IV
- Pyzchiva
- Remicade³
- Renflexis
- Saphnelo
- Selarsdi
- Simponi Aria
- Skyrizi IV
- Spevigo
- Stelara³
- Tofidence
- Tremfya IV
- Tyenne IV
- Wezlana

Multiple Sclerosis

- Briumvi
- Ocrevus
- Ocrevus Zunovo
- Tyruko
- Tysabri

Myasthenia Gravis

- Rystiggo

Neutropenia

- Fulphila
- Fylnetra
- Grastofil⁴
- Lapelga⁴
- Leukine
- Lupifil-P⁴
- Neulasta³
- Neulasta Onpro
- Neupogen
- Nivestym
- Nypozi
- Nyvepria
- plinabulin⁴
- Releuko
- Rolvedon
- Ryzneuta
- Stimufend
- Udenyca
- Udenyca Onbody
- Ziextenzo

Ophthalmic Agents

- abicipar⁴
- Ahzantive
- Beovu
- Byooviz
- Cimerli
- Enzeevu
- Eylea³
- Eylea HD
- Iluvien
- Izervay
- Lucentis³
- Opuviz
- Ozurdex
- Pavblu
- Retisert
- revakinagene taroretcel⁴
- Susvimo
- Syfovre
- Tepezza
- Vabysmo
- Visudyne
- Xipere
- Xlucane⁴
- Yesafili
- Yutiq

Pulmonary Arterial Hypertension

- Flolan
- Remodulin
- Revatio
- Trevyent⁴
- Tyvaso
- Uptravi IV
- Veletri
- Ventavis

Respiratory Agents

- Cinqair
- Xolair

Substance Use Disorder Agents

- Brixadi
- Probuphine
- Sublocade
- Vivitrol

Thrombocytopenia

- Nplate

Miscellaneous Therapeutic Agents

- Adakveo
- Alferon N
- Amvuttra
- Bkemp
- Cosela
- Crysvita
- Enjaymo
- Epysqli
- Evkeeza
- Ilaris
- Izervay
- Kalbitor
- Krystexxa
- Leqvio
- marstacimab⁴
- Niktimvo
- Omisirge
- Onpattro
- Oxlummo
- Qutenza
- Reblozyl
- Rethymic
- Rytelo
- Scenesse
- Soliris³
- Spinraza
- Sylvant
- tablecleucel⁴
- Ultomiris
- Uplizna
- Veopoz
- Vyepiti
- Xiaflex
- Zilretta
- Zulresso

¹ All drugs that can be classified under this header require cost-sharing. This includes any unlisted brand or generic names, as well as new drugs that are approved by the U.S. Food and Drug Administration (FDA) in that class during the course of the benefit year.

² Choosing one of these preferred brands does not affect the member's cost-sharing amount for the drug.

³ Cost-sharing applies to all FDA-approved biosimilars to this reference product.

⁴ Pending approval from the FDA.

Coverage issued by AmeriHealth HMO, Inc. and/or AmeriHealth Insurance Company of New Jersey.

Questions about cost-sharing amounts?

1-800-275-2583 (TTY: 711)

